SM 2280
Alternative Names: SM-2280Latest Information Update: 02 May 2024
At a glance
- Originator Beijing StarMab BioMed Technology
- Class Antineoplastics; Immunotherapies; Single-domain antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 23 Apr 2024 Early research in Solid tumours in China (Parenteral) prior to April 2024 (Beijing StarMab Biomed Technology pipeline, April 2024)